p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids)

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 39

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

277

HTML

2062

Figures (1-1)

212

Tables (1-4)

204

Sum=2755

Oct 21, 2006 (publication date) through Oct 4, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. Oct 21, 2006; 12(39): 6280-6284
Published online Oct 21, 2006. doi: 10.3748/wjg.v12.i39.6280

Table 2 Accompanying histopathologic features

Pathology	Patients (n)	Rate (%)
Atrophy	8	50.0
Neuroendocrine hyperplasia	7	43.8
Intestinal metaplasia	9	56.3
Neuroendocrine dysplasia	3	18.8
Multifocality	5	31.4
Submucosal extension	8	50.0

Citation: Doganavsargil B, Sarsik B, Kirdok FS, Musoglu A, Tuncyurek M. p21 and p27 immunoexpression in gastric well differentiated endocrine tumors (ECL-cell carcinoids). World J Gastroenterol 2006; 12(39): 6280-6284
URL: https://www.wjgnet.com/1007-9327/full/v12/i39/6280.htm
DOI: https://dx.doi.org/10.3748/wjg.v12.i39.6280